COYA (Coya Therapeutics) Loans Receivable: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COYA Coya Therapeutics Inc COYA
49 GF Score
Price $4.39
GF Value $6.54
Valuation Significantly Undervalued
View Full Analysis

What is Coya Therapeutics Loans Receivable?

Coya Therapeutics COYA -3.10% 49 Loans Receivable is $0.00 Mil as of Jun. 2026. GuruFocus rates COYA with a GF Score™ of 49/100 and a GF Value™ of $6.54 (Significantly Undervalued).

Coya Therapeutics's Loans Receivable for the quarter that ended in Jun. 2026 was $0.00 Mil.

Coya Therapeutics Loans Receivable Related Terms

Coya Therapeutics Loans Receivable Historical Data

* Premium members only.

The historical data trend for Coya Therapeutics's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coya Therapeutics Loans Receivable Chart

Coya Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Coya Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
COYA
49GF Score
Coya Therapeutics Inc COYA
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coya Therapeutics Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
Coya Therapeutics (COYA) has a Loans Receivable of $0.00 Mil as of Jun. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Coya Therapeutics and its competitors.
Is Coya Therapeutics' Loans Receivable too high?
Coya Therapeutics' current Loans Receivable is $0.00 Mil. Overall, Coya Therapeutics has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coya Therapeutics' Loans Receivable compare to ONCY and GUTS?
Coya Therapeutics' Loans Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Coya Therapeutics and its competitors. Coya Therapeutics's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coya Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Coya Therapeutics (COYA) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.54, compared to a current price of $4.39 — trading 32.9% below its estimated fair value. The current Loans Receivable is $0.00 Mil. Coya Therapeutics' overall GF Score™ is 49/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Coya Therapeutics (COYA), the current Loans Receivable is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coya Therapeutics (COYA) Overvalued in 2026?

Based on GuruFocus' analysis, Coya Therapeutics stock appears to be undervalued. The current stock price of $4.39 is trading 32.9% below its estimated GF Value™ of $6.54. GuruFocus considers Coya Therapeutics to be Significantly Undervalued.

Key valuation signals for COYA:

  • Loans Receivable: $0.00 Mil
  • GF Value™: $6.54 vs. price of $4.39 (32.9% below fair value)
  • GF Score™: 49/100

No single metric tells the full story. See the COYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coya Therapeutics Business Description

Address 5850 San Felipe Street, Suite 500, Houston, TX, USA, 77057
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
49GF Score

Get the complete analysis for COYA

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.39
Price
$6.54
GF Value